Dr. Julie Kim
Claim this profileDartmouth Hitchcock Medical Center
Expert in Cancer
Studies Adult T-Cell Leukemia/Lymphoma
26 reported clinical trials
72 drugs studied
About Julie Kim
Education:
- Obtained MD from the Geisel School of Medicine at Dartmouth in 2015.
- Completed Residency in Internal Medicine at Dartmouth-Hitchcock Medical Center in 2018.
- Finished Fellowship in Hematology and Oncology at Dartmouth-Hitchcock Medical Center in 2021.
Experience:
- Currently serving as an attending physician in Hematology and Oncology at Dartmouth-Hitchcock Medical Center.
Area of expertise
1Cancer
Global LeaderStage I
Stage II
Stage IV
2Adult T-Cell Leukemia/Lymphoma
NTRK1 positive
NTRK positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Julie Kim is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
More about Julie Kim
Clinical Trial Related8 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Julie Kim has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Radiation Therapy
- Dexamethasone
- Daunorubicin Hydrochloride
Breakdown of trials Julie Kim has run
Cancer
Adult T-Cell Leukemia/Lymphoma
Brain Tumor
Acute Lymphoblastic Leukemia
Neuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Julie Kim specialize in?
Is Julie Kim currently recruiting for clinical trials?
Are there any treatments that Julie Kim has studied deeply?
What is the best way to schedule an appointment with Julie Kim?
What is the office address of Julie Kim?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.